SANGAMO THERAPEUTICS INC (SGMO)

Company Profile

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 478 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; TX200, its wholly owned Chimeric Antigen Receptor (CAR), engineered regulatory T cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A., and BIVV003, its zinc finger nuclease, or ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD).

Company Info

SANGAMO THERAPEUTICS INC

7000 Marina Blvd

Brisbane California CALIFORNIA 94005

P: 15109706000

CEO: Alexander D. Macrae

Employees: 478

Website: https://www.sangamo.com/